Literature DB >> 16514773

Proceedings of the 4th Georg Rajka International Symposium on Atopic Dermatitis, Arcachon, France, September 15-17, 2005.

Alain Taïeb1, Jon Hanifin, Kevin Cooper, Jan D Bos, Genji Imokawa, Tim J David, Johannes Ring, Carlo Gelmetti, Alexander Kapp, Masutaka Furue, Yves de Prost, Ulf Darsow, Thomas Werfel, David Atherton, Arnold P Oranje.   

Abstract

The 4th Georg Rajka International Symposium on Atopic Dermatitis presented a comprehensive view of our current understanding and management of atopic dermatitis (AD). These proceedings highlight contributions related to the history of AD doctrines; genetic and epigenetic background; epidemiology; maturation of the immune system; infection and innate-adaptive immunity; epidermal inflammation, including neurogenic inflammation and pruritus; animal models; skin barrier; evidence-based therapy and education programs; prognostic and severity markers; and allergy testing. Several studies in animal models and human subjects point to impaired skin barrier function as a primary defect that facilitates the effect of environmental factors and immune dysregulation found in AD. The new frontier in AD therapy should, in the near future, reflect our better understanding of the skin barrier. The influence of environmental factors on the skin and other epithelial barriers in the perinatal period needs to be better understood to implement appropriate prevention programs.

Entities:  

Mesh:

Year:  2006        PMID: 16514773     DOI: 10.1016/j.jaci.2005.11.038

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  6 in total

Review 1.  Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence.

Authors:  Jonathan M Spergel; Donald Y M Leung
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

2.  Omalizumab for patients with severe and therapy-refractory atopic eczema?

Authors:  Christian Andres; Benedetta Belloni; Martin Mempel; Johannes Ring
Journal:  Curr Allergy Asthma Rep       Date:  2008-05       Impact factor: 4.806

3.  Filaggrin null mutations and childhood atopic eczema: a population-based case-control study.

Authors:  Sara J Brown; Caroline L Relton; Haihui Liao; Yiwei Zhao; Aileen Sandilands; Ian J Wilson; John Burn; Nick J Reynolds; W H Irwin McLean; Heather J Cordell
Journal:  J Allergy Clin Immunol       Date:  2008-03-04       Impact factor: 10.793

4.  Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6.

Authors:  Byung Eui Kim; Donald Y M Leung; Mark Boguniewicz; Michael D Howell
Journal:  Clin Immunol       Date:  2007-12-31       Impact factor: 3.969

5.  Filaggrin-stratified transcriptomic analysis of pediatric skin identifies mechanistic pathways in patients with atopic dermatitis.

Authors:  Christian Cole; Karin Kroboth; Nicholas J Schurch; Aileen Sandilands; Alexander Sherstnev; Grainne M O'Regan; Rosemarie M Watson; W H Irwin McLean; Geoffrey J Barton; Alan D Irvine; Sara J Brown
Journal:  J Allergy Clin Immunol       Date:  2014-05-28       Impact factor: 10.793

6.  Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity.

Authors:  Sean P Saunders; Tara Moran; Achilleas Floudas; Felicity Wurlod; Agnieszka Kaszlikowska; Maryam Salimi; Emma M Quinn; Christopher J Oliphant; Gabriel Núñez; Ross McManus; Emily Hams; Alan D Irvine; Andrew N J McKenzie; Graham S Ogg; Padraic G Fallon
Journal:  J Allergy Clin Immunol       Date:  2015-08-20       Impact factor: 10.793

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.